Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection

Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection

Tuberculosis (TB) remains a major health problem worldwide, and the development of effective vaccines is urgently needed. Vaccination strategies based on heterologous prime–boost protocols using Mycobacterium bovis bacillus Calmette-Guérin (BCG) as primer and modified vaccinia virus Ankara strain ex...

Full description

Bibliographic Details
Main Authors: Ming Zhang, Chunsheng Dong, Sidong Xiong
Format: Article
Language:English
Published: Taylor & Francis Group 2017-04-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
bcg
heterologous boosting
tuberculosis
vaccine
vsv-846
Online Access:http://dx.doi.org/10.1080/21645515.2016.1261229

Internet

http://dx.doi.org/10.1080/21645515.2016.1261229

Similar Items